A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma

NCT ID: NCT07107178

Last Updated: 2025-08-06

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 58 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-08-08
• Study Completion Date: 2027-08-31

Brief Summary

The goal of this clinical trial is to learn about the safety, tolerability and preliminary effectiveness of a treatment for patients with advanced melanoma,regardless of gender, aged between 18 and 75 years (inclusive).

Participants will receive the investigational product intravenously every two or three weeks. The treatment will continue for a maximum of two years for those who do not show signs of disease progression or experience intolerable side effects.

Conditions

Advanced Melanoma; Advanced Solid Tumor

Study Design

• Allocation Method: NA
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

dose escalation and expansion

Group Type: EXPERIMENTAL

BT02

Intervention Type: DRUG

monoclonal antibody injection with intravenous administration every 2 or 3 weeks

Interventions

BT02

monoclonal antibody injection with intravenous administration every 2 or 3 weeks

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Patients with histologically or cytologically confirmed diagnosis of unresectable locally advanced or metastatic malignant melanoma (except for uveal melanoma) who have failed in the prior systemic therapy .

2. Adequate organ and hematologic function.

3. At least 1 extracranial measurable lesion.

4. An ECOG activity status score of 0-1.

5. A life expectancy of ≥ 3 months.

6. Eligible participants of childbearing potential (both males and females) must agree to using effective contraception throughout the study period.

7. Good compliance and willingness to follow up.

Exclusion Criteria

1. Prior to first dose, received systemic antitumor therapy , scheduled major surgical procedure within 4 weeks , received systemic immunostimulants within 5 half-lives and systemic corticosteroids or other immunosuppressive medications within 14 days.

2. A history of active autoimmune disease within the past 2 years.

3. A history of clinically significant cardiovascular disease, severe cardiac rhythm/conduction abnormalities or LVEF<50%. A history of severe pulmonary disease that may lead to severe episodes of dyspnea.

4. A severe acute or chronic infection when enrollment.

5. Remaining the toxic reaction in previous anti-tumor therapy that has not recovered to ≤ Grade 1 .

6. Unresolved > grade 1 irAE or the history of a grade ≥ 3 irAE in previous immunotherapy, or known hypersensitivity to the formulation of the investigational product.

7. Clinically active CNS metastases or meningeal metastases.

8. A history of other type of malignancies.

9. Received a live attenuated vaccine within 28 days prior to the administration of the investigational product.

10. Poor compliance.

11. A history of alcohol/drugs abuse.

12. Current pregnancy or breastfeeding.

13. Other severe physical or mental illnesses or abnormal laboratory test results that the investigator deems unsuitable for participation in this study considering safety and compliance.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Peking University Cancer Hospital and Institute

OTHER

Sponsor Role: collaborator

Biotroy Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jun Guo, MD

Role: PRINCIPAL_INVESTIGATOR

Peking University Cancer Hospital & Institute

Central Contacts

Clinical development director

Role: CONTACT

clin.oper@biotroy.cn

+86-18602185973

Other Identifiers

BT02-102

Identifier Type: -

Identifier Source: org_study_id